24/7 suggests eight biotech trading near $5 with big upside potential


24/7's Lee Jackson pinpoints eight small-cap biotech ideas, whose stocks all trade near $5 but with big upside potential; each company has promising clinical trials and in some cases FDA-approved products already on the market or soon to arrive.

Galena Biopharma (GALE) "may be the home run that biotech investors are looking for," and the stock may be an acquisition target; Novavax (NVAX) has six vaccine candidates undergoing clinical trials and a seventh being readied for a Phase I study later this year.

Jackson's other favorite biotech opportunities: ARRY, BIOD, PLX, RIGL, SNTA, ZGNX.

J.P. Morgan has three different ideas for aggressive risk-tolerant investors: ITMN, NPSP and PLX.

From other sites
Comments (15)
  • al roman
    , contributor
    Comments (16206) | Send Message
     
    JPM's risk tolerant give a good balance and comparison,Bio-techs can be very fast moving.
    8 Feb 2014, 08:28 AM Reply Like
  • LYogi
    , contributor
    Comments (3098) | Send Message
     
    $ARIA isn't on this list (currently trading at $8) with buyout rumours and activist shareholder drama going on.

     

    keep a close eye on it!
    8 Feb 2014, 10:14 AM Reply Like
  • ScottyGreen
    , contributor
    Comments (111) | Send Message
     
    Like ARIA too, but it is higher than the $5 per share mentioned. Great potential on company alone (so many ppl were focused on b/o rumors, but it stands alone on sales/re-approval of drug/australia sales/awesome potential gap fill.
    9 Feb 2014, 01:56 PM Reply Like
  • Walkingwounded
    , contributor
    Comments (270) | Send Message
     
    Missed the 5.00 cut off, did you.
    8 Feb 2014, 12:53 PM Reply Like
  • deercreekvols
    , contributor
    Comments (9285) | Send Message
     
    A week ago, Galena was showing "red flags" according to an SA Top Pick article. Several other analysts (?) chimed in against Galena and the stock dropped rapidly.

     

    I am hoping this positive news pulls Galena back to where it once was. Sketchy "news" by several shorts has been shown to be untrue.

     

    Time for (GALE) to take off.
    8 Feb 2014, 01:11 PM Reply Like
  • pwd9398
    , contributor
    Comments (86) | Send Message
     
    Abstral sales are already at 5% according to Orexo's Q4 report, highest since the drug hit market in 2011. Could show some real revenue for $GALE, and i have a feeling the news is still spreading since it has come from Orexo and not Galena itself... could see a nice continuation of the run-up on Monday as more people catch on.

     

    Also, if sales for Galena are anywhere close to what Orexo is making it seem like, it would seem to discredit Matt Gravitt/Chet Stedman (GALE-shorting author of the "Red Flags" article), who claimed to have seen Abstral sales figures that suggested 0.5% market share rather than 5%.
    8 Feb 2014, 01:39 PM Reply Like
  • pwd9398
    , contributor
    Comments (86) | Send Message
     
    If there was any good to come out of that "Red Flags" article and the ensuing comment chaos, it is that a) I'm more confident in GALE after doing some more dd and b) made me aware of just how bad The Street articles are.
    8 Feb 2014, 01:42 PM Reply Like
  • Gman123456
    , contributor
    Comments (34) | Send Message
     
    I used " The Street articles" to know where the short are. To me that group work as a team to drive down a stock to sale short then they do day trades as it moves back up. I am long on Galena looking for $ 8.00 + per share this year. If there is a acquisition i target it at $ 11.00 + and see Galena passing on that price.
    8 Feb 2014, 02:24 PM Reply Like
  • docrog123
    , contributor
    Comments (150) | Send Message
     
    pwd; welcome aboard! u r right on the money with that last comment. I see them as ruthless outlaws who stay up drinking all night then come straight into work and worse than flying by the seat of their pants, they just make up lies to fill the pages. The real killer for me is that I used to believe everything they said! I wonder who really pays their salaries?
    8 Feb 2014, 09:15 PM Reply Like
  • rheimerl
    , contributor
    Comments (473) | Send Message
     
    gale headed to $10 plus... just hold on to your shares!
    8 Feb 2014, 07:21 PM Reply Like
  • traderof
    , contributor
    Comments (5) | Send Message
     
    Any thoughts on CTIC?
    9 Feb 2014, 12:38 PM Reply Like
  • elico868
    , contributor
    Comment (1) | Send Message
     
    ZGNX Is the best pick they have blockbuster pain drug FDA approved waiting for marketing next month !
    JMHO
    9 Feb 2014, 12:39 PM Reply Like
  • ScottyGreen
    , contributor
    Comments (111) | Send Message
     
    Go ZGNX and GALE, long here both.

     

    Can't wait till zogenix zohydro er starts selling in march and when the new anti-abuse formulation is complete.

     

    ZGNX T/A looks like it's ready to break out of a trading box/consolidation pattern to new highs any day now, might be the last chance to get it below $5ps before it pops again and stays on top of $5. GALE looking like an attractive swing now too.
    9 Feb 2014, 01:51 PM Reply Like
  • Cala
    , contributor
    Comments (31) | Send Message
     
    So SA when is the next hit piece on GALE? Expect The Street will have one soon.
    9 Feb 2014, 08:03 PM Reply Like
  • Mork747
    , contributor
    Comments (2) | Send Message
     
    What ever happened to Hollis Eden? 60 minutes was so bullish on them during the Bush years. I think they are now ticker HRBR but absolutely nothing seems to be getting out to the street. Any ideas?
    20 Feb 2014, 10:26 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs